Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Shubham Pant(The University of Texas MD Anderson Cancer Center), Christophe Le Tourneau(Institut Curie), Ademi Santiago-Walker(Johnson & Johnson (United States)), Spyros Triantos(Janssen (United States)), Marcelo Corassa, Josep Tabernero(Deaconess Hospital), Denis L. Jardim(Hospital Sírio-Libanês), Martin Gutierrez(Hackensack University Medical Center), Yohann Loriot(Institut Gustave Roussy), Martin Schüler(German Cancer Research Center), Kim Stuyckens(Janssen (Belgium)), Iwona Ługowska(The Maria Sklodowska-Curie National Research Institute of Oncology), Shibu Thomas(Janssen (United States)), Sylvie Rottey(Ghent University Hospital), Dirk Arnold(Asklepios Klinik Altona), David A. Reardon(Dana-Farber Cancer Institute), Hans Prenen(Antwerp University Hospital), Katsuki Arima Tiscoski, Gopa Iyer(Memorial Sloan Kettering Cancer Center), Christos S. Karapetis(Clínica Alemana), Hussein Sweiti(Janssen (United States)), Christopher D. Hart, Anna Minchom(Royal Marsden NHS Foundation Trust), Helen Winter(Hackensack University Medical Center), Alison Y. Zhang(The University of Sydney), Milena Perez Mak, Constance Hammond(Inserm), Baoshi Chen, Saltanat Najmi(Janssen (United States)), Anthony M. Joshua(St Vincent's Hospital Sydney), Herui Yao(Sun Yat-sen University), Christophe Massard(Institut Gustave Roussy), Jing Huang(First Affiliated Hospital of Henan University), Wei Fu(Janssen (United States)), Dong Yan(Nanjing University of Chinese Medicine), Lauren Crow(Janssen (Belgium)), Haiping Jiang, Yu Yang, Jean‐Charles Goeminne, Olaf Witt(German Cancer Research Center), Martin Alberto Greco(Inserm), Omar Carranza(Hospital Privado de Comunidad), Toshihiko Doi(National Cancer Center Hospital East), Jean‐Pascal Machiels(Cliniques Universitaires Saint-Luc), Graziela Zibetti Dal Molin
Cited by 195
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k